Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders

Addiction Science & Clinical Practice

Katherine A Belendiuk¹  Lisa L Baldini²  Marcel O Bonn-Miller³ 

[1] Institute of Human Development, University of California, 1121 Tolman Hall #1690, Berkeley 94720, CA, USA

[2] Palo Alto University, 1791 Arastradero Road, Palo Alto 94304, CA, USA

[3] Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, 3440 Market Street, Philadelphia 19104, PA, USA

关键词: PTSD;    Post-traumatic stress disorder;    Vomiting;    Nausea;    Pain;    MS;    Multiple sclerosis;    AIDS;    HIV;    HCV;    Hepatitis C virus;    Glaucoma;    Seizures;    Epilepsy;    Cancer, Crohn’s disease;    Cachexia;    ALS;    Alzheimer’s disease;    Treatment;    Medicine;    Marijuana;    Medical marijuana;    Cannabis;   

Others  :  1174769
DOI  :  10.1186/s13722-015-0032-7

 received in 2014-08-29, accepted in 2015-04-15,  发布年份 2015

【 摘 要 】

The present investigation aimed to provide an objective narrative review of the existing literature pertaining to the benefits and harms of marijuana use for the treatment of the most common medical and psychological conditions for which it has been allowed at the state level. Common medical conditions for which marijuana is allowed (i.e., those conditions shared by at least 80 percent of medical marijuana states) were identified as: Alzheimer’s disease, amyotrophic lateral sclerosis, cachexia/wasting syndrome, cancer, Crohn’s disease, epilepsy and seizures, glaucoma, hepatitis C virus, human immunodeficiency virus/acquired immunodeficiency syndrome, multiple sclerosis and muscle spasticity, severe and chronic pain, and severe nausea. Post-traumatic stress disorder was also included in the review, as it is the sole psychological disorder for which medical marijuana has been allowed. Studies for this narrative review were included based on a literature search in PsycINFO, MEDLINE, and Google Scholar. Findings indicate that, for the majority of these conditions, there is insufficient evidence to support the recommendation of medical marijuana at this time. A significant amount of rigorous research is needed to definitively ascertain the potential implications of marijuana for these conditions. It is important for such work to not only examine the effects of smoked marijuana preparations, but also to compare its safety, tolerability, and efficacy in relation to existing pharmacological treatments.

【 授权许可】

   
2015 Belendiuk et al.; licensee BioMed Central.

【 参考文献 】

• [1]Substance Abuse and Mental Health Services Administration: Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. Department of Health and Human Services, Rockville, MD. U.S; 2013.
• [2]Bonn-Miller MO, Harris AH, Trafton JA: Prevalence of cannabis use disorder diagnoses among veterans in 2002, 2008, and 2009. Psycholog Serv 2012, 9:404-16.
• [3]Johnston LD, O'Malley PM, Miech RA, Bachman JG, Schulenberg JE: Monitoring the Future national results on drug use: 1975–2013: Overview, Key Findings on Adolescent Drug Use. Institute for Social Research, The University of Michigan, Ann Arbor; 2014.
• [4]Volkow ND, Baler RD, Compton WM, Weiss SR: Adverse health effects of marijuana use. N Engl J Med 2014, 370:2219-27.
• [5]Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, et al.: Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the guideline development subcommittee of the American academy of neurology. Neurology 2014, 82:1556-63.
• [6]Procon.org. 23 legal medical marijuana states and DC: Laws, fees, and possession limits. Retrieved April 9, 2015, from [http://medicalmarijuana.procon.org/view.resource.php?resourceID=000881]
• [7]Bonn-Miller MO, Boden MT, Bucossi MM, Babson KA: Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. Am J Drug Alcohol Abuse 2014, 40:23-30.
• [8]Ilgen MA, Bohnert K, Kleinberg F, Jannausch M, Bohnert ASB, Walton MA, et al.: Characteristics of adults seeking medical marijuana certification. Drug Alcohol Depend 2013, 132:654-9.
• [9]Nunberg H, Kilmer B, Pacula RL, Burgdorf J: An analysis of applicants presenting to a medical marijuana specialty practice in California. J Drug Policy Anal. 2011, 4:1.
• [10]Minati L, Edginton T, Bruzzone MG, Giaccone G: Reviews: current concepts in Alzheimer's disease: a multidisciplinary review. Am J Alzheimers Dis Other Demen 2009, 24:95-121.
• [11]Fagan SG, Campbell VA: The influence of cannabinoids on generic traits of neurodegeneration. Br J Pharmacol 2014, 171:1347-60.
• [12]Gowran A, Noonan J, Campbell VA: The multiplicity of action of cannabinoids: implications for treating neurodegeneration. CNS Neurosci Ther 2011, 17:637-44.
• [13]Aso E, Ferrer I: Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic. Front Pharmacol 2014, 5:37.
• [14]Krishnan S, Cairns R, Howard R: Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev 2009, 2:CD007204.
• [15]Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ: Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry 1997, 12:913-9.
• [16]Walther S, Schüpbach B, Seifritz E, Homan P, Strik W: Randomized, controlled crossover trial of dronabinol, 2.5 mg, for agitation in 2 patients with dementia. J Clin Psychopharmacol 2011, 31:256-8.
• [17]Carter GT, Abood ME, Aggarwal SK, Weiss MD: Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials. Am J Hosp Palliat Care 2010, 27:347-56.
• [18]Carter GT, Rosen BS: Marijuana in the management of amyotrophic lateral sclerosis. Am J Hosp Palliat Care 2001, 18:264-70.
• [19]Amtmann D, Weydt P, Johnson KL, Jensen MP, Carter GT: Survey of cannabis use in patients with amyotrophic lateral sclerosis. Am J Hosp Palliat Care 2004, 21:95-104.
• [20]Weber M, Goldman B, Truniger S: Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial. J Neurol Neurosurg Psychiatry 2010, 81:1135-40.
• [21]Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, et al.: Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med 2003, 139:258-66.
• [22]Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, et al.: Dronabinol and marijuana in HIV-positive marijuana smokers: caloric intake, mood, and sleep. J Acquir Immune Defic Syndr 2007, 45:545-54.
• [23]Foltin RW, Fischman MW, Byrne MF: Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite 1988, 11:1-14.
• [24]Haney M: Effects of smoked marijuana in healthy and HIV+ marijuana smokers. J Clin Pharmacol 2002, 42:34S-40.
• [25]Bedi G, Foltin RW, Gunderson EW, Rabkin J, Hart CL, Comer SD, et al.: Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study. Psychopharmacol (Berl) 2010, 212:675-86.
• [26]Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, et al.: Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995, 10:89-97.
• [27]Beal JE, Olson R, Lefkowitz L, Laubenstein L, Bellman P, Yangco B, et al.: Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 1997, 14:7-14.
• [28]Riggs PK, Vaida F, Rossi SS, Sorkin LS, Gouaux B, Grant I, et al.: A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men. Brain Res 2012, 1431:46-52.
• [29]Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, et al.: Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a north central cancer treatment group study. J Clin Oncol 2002, 20:567-73.
• [30]Bowles DW, O’Bryant CL, Camidge DR, Jimeno A: The intersection between cannabis and cancer in the United States. Crit Rev Oncol Hematol 2012, 83:1-10.
• [31]Pisanti S, Malfitano AM, Grimaldi C, Santoro A, Gazzerro P, Laezza C, et al.: Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents. Best Prac Res Clin Endocrinol Metab 2009, 23:117-31.
• [32]McKallip RJ, Nagarkatti M, Nagarkatti PS: Δ-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol 2005, 174:3281-9.
• [33]Guzman M, Duarte MJ, Blazquez C, Ravina J, Rosa MC, Galve-Roperh I, et al.: A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer 2006, 95:197-203.
• [34]Storr M, Devlin S, Kaplan GG, Panaccione R, Andrews CN: Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease. Inflamm Bowel Dis 2014, 20:472-80.
• [35]Lal S, Prasad N, Ryan M, Tangri S, Silverberg MS, Gordon A, et al.: Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2011, 23:891-6.
• [36]Allegretti JR, Courtwright A, Lucci M, Korzenik JR, Levine J: Marijuana use patterns among patients with inflammatory bowel disease. Inflamm Bowel Dis 2013, 19:2809-14.
• [37]Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM: Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol 2013, 11:1276-80.
• [38]Hill TD, Cascio MG, Romano B, Duncan M, Pertwee RG, Williams CM, et al.: Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br J Pharmacol 2013, 170:679-92.
• [39]Jones NA, Glyn SE, Akiyama S, Hill TD, Hill AJ, Weston SE, et al.: Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure 2012, 21:344-52.
• [40]Wallace MJ, Blair RE, Falenski KW, Martin BR, DeLorenzo RJ: The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther 2003, 307:129-37.
• [41]Jones NA, Hill AJ, Smith I, Bevan SA, Williams CM, Whalley BJ, et al.: Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther 2010, 332:569-77.
• [42]Gordon E, Devinsky O: Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia 2001, 42:1266-72.
• [43]Hamerle M, Ghaeni L, Kowski A, Weissinger F, Holtkamp M: Cannabis and other illicit drug use in epilepsy patients. Eur J Neurol 2014, 21:167-70.
• [44]Gross DW, Hamm J, Ashworth NL, Quigley D: Marijuana use and epilepsy: prevalence in patients of a tertiary care epilepsy center. Neurology 2004, 62:2095-7.
• [45]Gloss D, Vickrey B: Cannabinoids for epilepsy. Cochrane Database Syst Rev 2014, 3:CD009270.
• [46]Mechoulam R, Carlini EA: Toward drugs derived from cannabis. Naturwissenschaften 1978, 65:174-9.
• [47]Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, et al.: Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980, 21:175-85.
• [48]Ames FR, Cridland S: Anticonvulsant effect of cannabidiol. S Afr Med J 1986, 69:14.
• [49]Merritt JC, Crawford WJ, Alexander PC, Anduze AL, Gelbart SS: Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology 1980, 87:222-8.
• [50]Hepler RS, Frank IR: Marihuana smoking and intraocular pressure. JAMA 1971, 217:1392.
• [51]Green K: Marijuana smoking vs cannabinoids for glaucoma therapy. Arch Ophthalmol 1998, 116:1433-7.
• [52]Nucci C, Bari M, Spanò A, Corasaniti M, Bagetta G, Maccarrone M, et al.: Potential roles of (endo) cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection. Prog Brain Res 2008, 173:451-64.
• [53]Flach AJ: Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma. Trans Am Ophthalmol Soc 2002, 100:215-22.
• [54]Jampel H: American glaucoma society position statement: marijuana and the treatment of glaucoma. J Glaucoma 2010, 19:75-6.
• [55]Buys YM, Rafuse PE: Canadian ophthalmological society policy statement on the medical use of marijuana for glaucoma. Can J Ophthalmol 2010, 45:324-6.
• [56]Tomida I, Pertwee RG, Azuara-Blanco A: Cannabinoids and glaucoma. Br J Ophthalmol 2004, 88:708-13.
• [57]Brunet L, Moodie EE, Rollet K, Cooper C, Walmsley S, Potter M, et al.: Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: a longitudinal cohort analysis. Clin Infect Dis 2013, 57:663-70.
• [58]Hézode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani E-S, et al.: Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005, 42:63-71.
• [59]Hézode C, Zafrani ES, Roudot-Thoraval F, Costentin C, Hessami A, Bouvier–Alias M, et al.: Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 2008, 134:432-9.
• [60]Ishida JH, Peters MG, Jin C, Louie K, Tan V, Bacchetti P, et al.: Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol 2008, 6:69-75.
• [61]Costiniuk CT, Mills E, Cooper CL: Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus. Can J Gastroenterol 2008, 22:376-80.
• [62]Sylvestre DL, Clements BJ, Malibu Y: Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. Eur J Gastroenterol Hepatol 2006, 18:1057-63.
• [63]Glue P: The clinical pharmacology of ribavirin. Semin Liver Dis 1998, 19S:17-24.
• [64]Wasley A, Grytdal S, Gallagher K: Centers for Disease Control and Prevention (CDC): Surveillance for acute viral hepatitis -- United States, 2006. MMWR Surveill Summ 2008, 57:1-24.
• [65]Prentiss D, Power R, Balmas G, Tzuang G, Israelski DM: Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting. J Acquir Immune Defic Syndr 2004, 35:38-45.
• [66]Lutge EE, Gray A, Siegfried N: The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. Cochrane Database Syst Rev 2013, 4:CD005175.
• [67]Bredt BM, Higuera-Alhino D, Shade SB, Hebert SJ, McCune JM, Abrams DI: Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. J Clin Pharmacol 2002, 42:82S-9.
• [68]Kosel BW, Aweeka FT, Benowitz NL, Shade SB, Hilton JF, Lizak PS, et al.: The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 2002, 16:543-50.
• [69]Bonn-Miller MO, Oser ML, Bucossi MM, Trafton JA: Cannabis use and HIV antiretroviral therapy adherence and HIV-related symptoms. J Behav Med 2014, 37:1-10.
• [70]Haney M, Rabkin J, Gunderson E, Foltin RW: Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. Psychopharmacology (Berl) 2005, 181:170-8.
• [71]Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, et al.: Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007, 68:515-21.
• [72]Ellis RJ, Toperoff W, Vaida F, van den Brande G, Gonzales J, Gouaux B, et al.: Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009, 34:672-80.
• [73]Struwe M, Kaempfer SH, Geiger CJ, Pavia AT, Plasse TF, Shepard KV, et al.: Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother 1993, 27:827-31.
• [74]Centers for Disease Control and Prevention (CDC). HIV and substance use in the United States. Retrieved April 9, 2015, from [http://www.cdc.gov/hiv/risk/behavior/substanceuse.html]
• [75]Pandyan AD, Gregoric M, Barnes MP, Wood D, van Wijck F, Burridge J, et al.: Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil 2005, 27:2-6.
• [76]Beard S, Hunn A, Wight J: Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess 2003, 7(40):1-111.
• [77]Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, et al.: A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols*(Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011, 18:1122-31.
• [78]Wade DT, Makela P, Robson P, House H, Bateman C: Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004, 10:434-41.
• [79]Collin C, Davies P, Mutiboko IK, Ratcliffe S: Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007, 14:290-6.
• [80]Wade DT, Collin C, Stott C, Duncombe P: Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 2010, 16:707-14.
• [81]Wade DT, Robson P, House H, Makela P, Aram J: A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003, 17:21-9.
• [82]Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, et al.: Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005, 76:1664-9.
• [83]Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, et al.: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003, 362:1517-26.
• [84]Pooyania S, Ethans K, Szturm T, Casey A, Perry D: A randomized, double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury. Arch Phys Med Rehabil 2010, 91:703-7.
• [85]Wade DT, Makela PM, House H, Bateman C, Robson P: Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006, 12:639-45.
• [86]Serpell MG, Notcutt W, Collin C: Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol 2013, 260:285-95.
• [87]Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R: A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex®(nabiximols). Mult Scler 2012, 18:219-28.
• [88]Flachenecker P, Henze T, Zettl UK: Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice—results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol 2014, 71:271-9.
• [89]Rog DJ, Nurmikko TJ, Friede T, Young CA: Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005, 65:812-9.
• [90]Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, et al.: Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ 2012, 184:1143-50.
• [91]Greenberg HS, Werness SA, Pugh JE, Andrus RO, Anderson DJ, Domino EF: Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther 1994, 55:324-8.
• [92]Clark AJ, Ware MA, Yazer E, Murray TJ, Lynch ME: Patterns of cannabis use among patients with multiple sclerosis. Neurology 2004, 62:2098-100.
• [93]Page SA, Verhoef MJ, Stebbins RA, Metz LM, Levy JC: Cannabis use as described by people with multiple sclerosis. Can J Neurol Sci 2003, 30:201-5.
• [94]Pavisian B, MacIntosh BJ, Szilagyi G, Staines RW, O'Connor P, Feinstein A: Effects of cannabis on cognition in patients with MS: a psychometric and MRI study. Neurology 2014, 82:1879-87.
• [95]Honarmand K, Tierney MC, O'Connor P, Feinstein A: Effects of cannabis on cognitive function in patients with multiple sclerosis. Neurology 2011, 76:1153-60.
• [96]Rao SM, Leo GJ, Bernardin L, Unverzagt F: Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991, 41:685-91.
• [97]Leussink VI, Husseini L, Warnke C, Broussalis E, Hartung HP, Kieseier BC: Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity. Ther Adv Neurol Disord 2012, 5:255-66.
• [98]American Academy of Neurology. Position statement: Use of medical marijuana for neurologic disorders. Retrieved April 9, 2015, from [https://www.aan.com/uploadedFiles/Website_Library_Assets/Documents/6.Public_Policy/1.Stay_Informed/2.Position_Statements/3.PDFs_of_all_Position_Statements/Final%20Medical%20Marijuana%20Position%20Statement.pdf]
• [99]Bonn-Miller MO, Vujanovic AA, Feldner MT, Bernstein A, Zvolensky MJ: Posttraumatic stress symptom severity predicts marijuana use coping motives among traumatic event-exposed marijuana users. J Trauma Stress 2007, 20:577-86.
• [100]Bremner JD, Southwick SM, Darnell A, Charney DS: Chronic PTSD in Vietnam combat veterans: course of illness and substance abuse. Amer J Psychiatry 1996, 153:369-75.
• [101]Vandrey R, Babson KA, Herrmann ES, Bonn-Miller MO: Interactions between disordered sleep, post-traumatic stress disorder, and substance use disorders. Int Rev Psychiatry 2014, 26:237-47.
• [102]Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A, et al.: Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry 2013, 18:1034-40.
• [103]Passie T, Emrich HM, Karst M, Brandt SD, Halpern JH: Mitigation of post-traumatic stress symptoms by cannabis resin: a review of the clinical and neurobiological evidence. Drug Test Anal 2012, 4:649-59.
• [104]Roitman P, Mechoulam R, Cooper-Kazaz R, Shalev A: Preliminary, open-label, pilot study of add-on oral Δ-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin Drug Investig 2014, 34:587-91.
• [105]Fraser GA: The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther 2009, 15:84-8.
• [106]Jetly R, Heber A, Fraser G, Boisvert D: The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology 2015, 51:585-8.
• [107]Mashiah M. Medical cannabis as treatment for chronic combat PTSD: Promising results in an open pilot study [presentation]. Patients Out of Time Conference; Tuscon, Arizona; 2012.
• [108]Cougle JR, Bonn-Miller MO, Vujanovic AA, Zvolensky MJ, Hawkins KA: Posttraumatic stress disorder and cannabis use in a nationally representative sample. Psychol Addict Behav 2011, 25:554-8.
• [109]Boden MT, Babson KA, Vujanovic AA, Short NA, Bonn-Miller MO: Posttraumatic stress disorder and cannabis use characteristics among military veterans with cannabis dependence. Am J Addict 2013, 22:277-84.
• [110]Babson KA, Boden MT, Harris AH, Stickle TR, Bonn-Miller MO: Poor sleep quality as a risk factor for lapse following a cannabis quit attempt. J Subst Abuse Treat 2013, 44:438-43.
• [111]Babson KA, Boden MT, Bonn-Miller MO: The impact of perceived sleep quality and sleep efficiency/duration on cannabis use during a self-guided quit attempt. Addict Behav 2013, 38:2707-13.
• [112]Bonn-Miller MO, Boden MT, Vujanovic AA, Drescher KD: Prospective investigation of the impact of cannabis use disorders on posttraumatic stress disorder symptoms among veterans in residential treatment. Psychological Trauma: Theory, Research, Practice, and Policy 2013, 5:193-200.
• [113]Martín-Sánchez E, Furukawa TA, Taylor J, Martin JL: Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med 2009, 10:1353-68.
• [114]Phillips TJC, Cherry CL, Cox S, Marshall SJ, Rice ASC: Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS One 2010, 5:e14433.
• [115]Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, et al.: Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010, 182:E694-701.
• [116]Wallace M, Schulteis G, Atkinson JH, Wolfson T, Lazzaretto D, Bentley H, et al.: Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 2007, 107:785-96.
• [117]Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H: Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain 2013, 14:136-48.
• [118]Sallan SE, Zinberg NE, Frei E 3rd: Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 1975, 293:795-7.
• [119]Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I, et al.: Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate: a prospective, randomized evaluation. Ann Intern Med 1979, 91:819-24.
• [120]Orr LE, McKernan JF, Bloome B: Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch Intern Med 1980, 140:1431-3.
• [121]Ben Amar M: Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 2006, 105:1-25.
• [122]Machado Rocha FC, Stefano SC, De Cassia HR, Rosa Oliveira LM, Da Silveira DX: Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl) 2008, 17:431-43.
• [123]Tramèr MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ: Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001, 323:16-21.
• [124]Frytak S, Moertel CG, O'Fallon JR, Rubin J, Creagan ET, O'Connell MJ, et al.: Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med 1979, 91:825-30.
• [125]Ungerleider JT, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison K: Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. Cancer 1982, 50:636-45.
• [126]Meiri E, Jhangiani H, Vredenburgh JJ, Barbato LM, Carter FJ, Yang HM, et al.: Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 2007, 23:533-43.
• [127]Lane M, Vogel CL, Ferguson J, Krasnow S, Saiers JL, Hamm J, et al.: Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage 1991, 6:352-9.
• [128]Sun S, Zimmermann AE: Cannabinoid hyperemesis syndrome. Hosp Pharm 2013, 48:650-5.
• [129]Hejazi RA, McCallum RW: Review article: cyclic vomiting syndrome in adults–rediscovering and redefining an old entity. Aliment Pharmacol Ther 2011, 34:263-73.
• [130]Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al.: Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol 2011, 29:4189-98.
• [131]Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al.: Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Onco 2010, 21(5):232-43.
• [132]Gordon AJ, Conley JW, Gordon JM: Medical consequences of marijuana use: a review of current literature. Curr Psychiatry Rep 2013, 15:419.
• [133]Reinarman C, Nunberg H, Lanthier F, Heddleston T: Who are medical marijuana patients? Population characteristics from nine California assessment clinics. J Psychoactive Drugs 2011, 43:128-35.
• [134]Walsh Z, Callaway R, Belle-Isle L, Capler R, Kay R, Lucas P, et al.: Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. Int J Drug Policy 2013, 24:511-6.
• [135]Potter DJ, Clark P, Brown MB: Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci 2008, 53:90-4.
• [136]Hillig KW, Mahlberg PG: A chemotaxonomic analysis of cannabinoid variation in cannabis (Cannabaceae). Am J Bot 2004, 91:966-75.